{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:31:08Z","timestamp":1760016668015,"version":"3.37.3"},"reference-count":23,"publisher":"The Journal of Rheumatology","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>Magnetic resonance imaging (MRI) was used in a phase IIb study of baricitinib in patients with RA to support dose selection for the phase III program.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Three hundred one patients with active RA who were taking stable methotrexate were randomized 2:1:1:1:1 to placebo or once-daily baricitinib (1, 2, 4, or 8 mg) for up to 24 weeks. One hundred fifty-four patients with definitive radiographic erosion had MRI of the hand\/wrist at baseline and at weeks 12 and 24. Two expert radiologists, blinded to treatment and visit order, scored images for synovitis, osteitis, bone erosion, and cartilage loss. Combined inflammation (osteitis + 3\u00d7 synovitis score) and total joint damage (erosion + 2.5\u00d7 cartilage loss score) scores were calculated. Treatment groups were compared using ANCOVA adjusting for baseline scores.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Mean changes from baseline to Week 12 for synovitis were \u22120.10, \u22121.50, and \u22121.60 for patients treated with placebo, baricitinib 4 mg, and baricitinib 8 mg, respectively (p = 0.003 vs placebo for baricitinib 4 and 8 mg). Mean changes for osteitis were 0.00, \u22123.20, and \u22122.10 (p = 0.001 vs placebo for baricitinib 4 mg and p = 0.037 for 8 mg), respectively. Mean changes for bone erosion were 0.90, 0.10, and 0.40 (p = 0.089 for 4 mg and p = 0.275 for 8 mg), respectively, in these treatment groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>MRI findings in this subgroup of patients suggest suppression of synovitis, osteitis, and combined inflammation by baricitinib 4 and 8 mg. This corroborates previously demonstrated clinical efficacy of baricitinib and increases confidence that baricitinib 4 mg could reduce the radiographic progression in phase III studies. [Clinical trial registration number (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"www.ClinicalTrials.gov\" ext-link-type=\"uri\" xlink:type=\"simple\">www.ClinicalTrials.gov<\/jats:ext-link>):<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01185353\">NCT01185353<\/jats:ext-link>]<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.171469","type":"journal-article","created":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T17:26:06Z","timestamp":1547573166000},"page":"887-895","source":"Crossref","is-referenced-by-count":7,"title":["MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis"],"prefix":"10.3899","volume":"46","author":[{"given":"Charles","family":"Peterfy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6965-3611","authenticated-orcid":false,"given":"Julie","family":"DiCarlo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Emery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5294-4503","authenticated-orcid":false,"given":"Mark C.","family":"Genovese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward C.","family":"Keystone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter C.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8887-6477","authenticated-orcid":false,"given":"Doug E.","family":"Schlichting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott D.","family":"Beattie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Luchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Macias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2019,1,15]]},"reference":[{"key":"2019080109250519000_46.8.887.1","unstructured":"European Medicines Agency . Committee for Medicinal Products for Human Use. Guideline on clinical investigation of medicinal products other than NSAIDs for treatment of rheumatoid arthritis, draft. [Internet. Accessed March 18, 2019.] Available from: www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2015\/06\/WC500187583.pdf"},{"key":"2019080109250519000_46.8.887.2","doi-asserted-by":"publisher","DOI":"10.1002\/art.30634"},{"key":"2019080109250519000_46.8.887.3","doi-asserted-by":"publisher","DOI":"10.1002\/art.21678"},{"key":"2019080109250519000_46.8.887.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203444"},{"key":"2019080109250519000_46.8.887.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202696"},{"key":"2019080109250519000_46.8.887.6","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1002\/art.38083","article-title":"Review: the utility of magnetic resonance imaging for assessing structural damage in randomized controlled trials in rheumatoid arthritis","volume":"65","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2019080109250519000_46.8.887.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201611"},{"key":"2019080109250519000_46.8.887.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204762"},{"key":"2019080109250519000_46.8.887.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206478"},{"key":"2019080109250519000_46.8.887.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210094"},{"key":"2019080109250519000_46.8.887.11","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"2019080109250519000_46.8.887.12","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2019080109250519000_46.8.887.13","first-page":"1385","article-title":"OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system","volume":"30","author":"\u00d8stergaard","year":"2003","journal-title":"J Rheumatol"},{"key":"2019080109250519000_46.8.887.14","doi-asserted-by":"publisher","DOI":"10.1186\/ar3861"},{"key":"2019080109250519000_46.8.887.15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew030"},{"key":"2019080109250519000_46.8.887.16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206015"},{"key":"2019080109250519000_46.8.887.17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.018457"},{"key":"2019080109250519000_46.8.887.18","doi-asserted-by":"publisher","DOI":"10.1186\/ar2555"},{"key":"2019080109250519000_46.8.887.19","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.146043"},{"key":"2019080109250519000_46.8.887.20","doi-asserted-by":"publisher","DOI":"10.1002\/art.30402"},{"key":"2019080109250519000_46.8.887.21","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration . Guidance for industry: rheumatoid arthritis: developing drug products for treatment. [Internet. Accessed March 18, 2019.] Available from: www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm354468.pdf"},{"key":"2019080109250519000_46.8.887.22","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141009"},{"key":"2019080109250519000_46.8.887.23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-eular.2216"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.171469","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T03:17:35Z","timestamp":1720927055000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.171469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,15]]},"references-count":23,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8,1]]},"published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.3899\/jrheum.171469"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.171469","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"type":"print","value":"0315-162X"},{"type":"electronic","value":"1499-2752"}],"subject":[],"published":{"date-parts":[[2019,1,15]]}}}